Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Zeng, Haiyan; Li, Lei; Hou, Zhouhua; Zhang, Yapeng; Tang, Zhongxiang; Liu, Shuiping

doi:10.7150/ijms.43079



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2020; 17(7):892-902. doi:10.7150/ijms.43079 This issue Cite

Review

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Haiyan Zeng^1,2, Lei Li², Zhouhua Hou¹, Yapeng Zhang², Zhongxiang Tang², Shuiping Liu^1,2✉

1. Department of Infectious Disease, Xiangya Hospital, Central South University, Changsha 410008, China
2. Department of Microbiology, School of Basic Medical Science, Central South University, Changsha 410078, China

Citation:

Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci 2020; 17(7):892-902. doi:10.7150/ijms.43079. https://www.medsci.org/v17p0892.htm

Other styles

Abstract

Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance.

Keywords: hepatitis C virus (HCV), direct acting antiviral (DAA), sustained virological response (SVR), resistance-associated substitutions (RAS)

Citation styles

APA

Zeng, H., Li, L., Hou, Z., Zhang, Y., Tang, Z., Liu, S. (2020). Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. International Journal of Medical Sciences, 17(7), 892-902. https://doi.org/10.7150/ijms.43079.

ACS

Zeng, H.; Li, L.; Hou, Z.; Zhang, Y.; Tang, Z.; Liu, S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int. J. Med. Sci. 2020, 17 (7), 892-902. DOI: 10.7150/ijms.43079.

NLM

CSE

Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. 2020. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci. 17(7):892-902.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.